

## Supplementary Appendix

Supplementary Table 1. SUS Acute respiratory illness ICD10 code list.

SUS Acute respiratory illness ICD10 code list	
J04*	Acute laryngitis and tracheitis
J09*	Influenza due to identified avian influenza virus
J10*	Influenza with pneumonia, other influenza virus identified
J11*	Influenza with pneumonia, virus not identified
J12*	Viral pneumonia, not elsewhere classified
J13*	Pneumonia due to <i>Streptococcus pneumoniae</i>
J14*	Pneumonia due to <i>Haemophilus influenzae</i>
J15*	Bacterial pneumonia, not elsewhere classified
J16*	Pneumonia due to other infectious organisms, not elsewhere classified
J17*	Pneumonia in diseases classified elsewhere
J18*	Pneumonia, organism unspecified
J20*	Acute bronchitis
J21*	Acute bronchiolitis
J22*	Unspecified acute lower respiratory infection
J80*	ARDS (related to respiratory infection)
U071, U072	COVID-19, virus identified and not identified
U04*	Severe acute respiratory syndrome (SARS)


Supplementary Table 2. Descriptive characteristics of those included the absolute vaccine effectiveness (aVE) analysis of the duration of protection of the monovalent vaccines.

			Overall		Controls		Cases	
			n	%	n	%	n	%
Vaccination Status	No. of doses	Interval since last dose	63,251	100%	43,410	69%	19,841	31%
	Unvaccinated	n/a	4,848	7.7%	2,805	6.5%	2,043	10.3%
	2	0-13 days	1	0.0%	0	0.0%	1	0.0%
		2 -11 weeks	59	0.1%	44	0.1%	15	0.1%
		3-5 months	191	0.3%	150	0.3%	41	0.2%
		6 - 8 months	387	0.6%	266	0.6%	121	0.6%
		9- 11 months	652	1.0%	448	1.0%	204	1.0%
		12 - 14 months	1,682	2.7%	1,039	2.4%	643	3.2%
		15+ months	2,674	4.2%	1,913	4.4%	761	3.8%
	3+	0-13 days	647	1.0%	474	1.1%	173	0.9%
		2 -11 weeks	10,500	16.6%	7,848	18.1%	2,652	13.4%
		3-5 months	14,874	23.5%	10,409	24.0%	4,465	22.5%
		6 - 8 months	14,459	22.9%	9,143	21.1%	5,316	26.8%
		9- 11 months	10,240	16.2%	7,247	16.7%	2,993	15.1%
12 - 14 months		2,035	3.2%	1,624	3.7%	411	2.1%	
15+ months	2	0.0%	0	0.0%	2	0.0%		
Gender	Female		31,955	50.5%	22,083	50.9%	9,872	49.8%
	Male		30,846	48.8%	20,923	48.2%	9,923	50.0%
	Missing		450	0.7%	404	0.9%	46	0.2%
Age	18-19		207	0.3%	154	0.4%	53	0.3%
	20-24		572	0.9%	398	0.9%	174	0.9%
	25-29		747	1.2%	481	1.1%	266	1.3%
	30-34		949	1.5%	668	1.5%	281	1.4%
	35-39		1,072	1.7%	804	1.9%	268	1.4%
	40-44		1,256	2.0%	970	2.2%	286	1.4%
	45-49		1,518	2.4%	1,116	2.6%	402	2.0%
	50-54		2,339	3.7%	1,717	4.0%	622	3.1%
	55-59		3,192	5.0%	2,331	5.4%	861	4.3%
	60-64		4,210	6.7%	3,050	7.0%	1,160	5.8%
	65-69		5,149	8.1%	3,505	8.1%	1,644	8.3%
	70-74		7,183	11.4%	4,721	10.9%	2,462	12.4%
	75-79		8,875	14.0%	6,109	14.1%	2,766	13.9%
	80-84		9,253	14.6%	6,207	14.3%	3,046	15.4%
85-89		9,077	14.4%	5,974	13.8%	3,103	15.6%	
90+		7,652	12.1%	5,205	12.0%	2,447	12.3%	
Ethnicity	African		561	0.9%	380	0.9%	181	0.9%
	Any other Asian background		637	1.0%	435	1.0%	202	1.0%
	Any other Black background		279	0.4%	190	0.4%	89	0.4%
	Any other White background		3,194	5.0%	2,143	4.9%	1,051	5.3%
	Any other ethnic group		758	1.2%	518	1.2%	240	1.2%

	Any other mixed background	251	0.4%	171	0.4%	80	0.4%
	Bangladeshi or British Bangladeshi	327	0.5%	225	0.5%	102	0.5%
	British, Mixed British	50,773	80.3%	34,969	80.6%	15,804	79.7%
	Caribbean	634	1.0%	392	0.9%	242	1.2%
	Chinese	119	0.2%	74	0.2%	45	0.2%
	Indian or British Indian	1,335	2.1%	886	2.0%	449	2.3%
	Irish	754	1.2%	521	1.2%	233	1.2%
	Pakistani or British Pakistani	1,082	1.7%	763	1.8%	319	1.6%
	White and Asian	67	0.1%	43	0.1%	24	0.1%
	White and Black African	54	0.1%	32	0.1%	22	0.1%
	White and Black Caribbean	124	0.2%	84	0.2%	40	0.2%
	Missing	2,302	3.6%	1,584	3.6%	718	3.6%
NHS Region	East of England	5,716	9.0%	4,033	9.3%	1,683	8.5%
	London	8,243	13.0%	5,466	12.6%	2,777	14.0%
	Midlands	13,698	21.7%	9,353	21.5%	4,345	21.9%
	North East	11,407	18.0%	7,611	17.5%	3,796	19.1%
	North West	9,958	15.7%	7,168	16.5%	2,790	14.1%
	South East	8,027	12.7%	5,614	12.9%	2,413	12.2%
	South West	6,202	9.8%	4,165	9.6%	2,037	10.3%
IMD Quintiles	1	15,723	24.9%	10,872	25.0%	4,851	24.4%
	2	13,187	20.8%	9,048	20.8%	4,139	20.9%
	3	12,254	19.4%	8,385	19.3%	3,869	19.5%
	4	11,731	18.5%	8,030	18.5%	3,701	18.7%
	5	10,057	15.9%	6,873	15.8%	3,184	16.0%
	Missing	299	0.5%	202	0.5%	97	0.5%
Previously positive	None	50,553	79.9%	32,558	75.0%	17,995	90.7%
	Wild-type	1,622	2.6%	1,324	3.0%	298	1.5%
	Alpha	1,981	3.1%	1,590	3.7%	391	2.0%
	Delta	2,094	3.3%	1,710	3.9%	384	1.9%
	Omicron (before 1st April 2022)	5,347	8.5%	4,711	10.9%	636	3.2%
	Omicron (from 1st April 2022 onwards)	1,654	2.6%	1,517	3.5%	137	0.7%
Risk status	Healthcare worker	555	0.9%	383	0.9%	172	0.9%
	Carehome	2,460	3.9%	1,957	4.5%	503	2.5%
	CaaS autumn booster cohort	46,825	74.0%	31,271	72.0%	15,554	78.4%
	At risk - ever, from NIMS*	12,165	19.2%	8,705	20.1%	3,460	17.4%
	CEV	29,167	46.1%	20,005	46.1%	9,162	46.2%
	Severely immunosuppressed	8,074	12.8%	5,517	12.7%	2,557	12.9%

\*Only for those <65 years

Supplementary Figure 1. Cases (those testing positive) and controls (those testing negative) over time in the analysis of duration of protection of the monovalent vaccines.



Supplementary Table 3. Absolute VE (aVE) against hospitalisation amongst those aged 65 years and older, without the adjustment for previous positivity.

Age	No. of doses	Interval since last dose	Controls	Cases	OR	VE
65+	Unvaccinated		1172	685	Baseline	Baseline
	2	0-13 days	0	0	n too small	n too small
		2 -11 weeks	4	0	n too small	n too small
		3-5 months	26	6	n too small	n too small
		6 - 8 months	33	10	0.45 (0.21-0.93)	55.4 (6.9 to 78.6)
		9- 11 months	80	28	0.51 (0.32-0.81)	48.8 (19.0 to 67.6)
		12 - 14 months	99	33	0.61 (0.4-0.93)	39.3 (7.3 to 60.3)
		15+ months	1282	504	0.66 (0.57-0.77)	33.9 (23.5 to 42.8)
	3+	0-13 days	3	0	n too small	n too small
		2 -11 weeks	647	183	0.29 (0.24-0.36)	70.6 (64.0 to 76.0)
		3-5 months	4598	2051	0.45 (0.4-0.5)	55.3 (49.5 to 60.3)
		6 - 8 months	2639	1168	0.6 (0.53-0.68)	40.3 (32.4 to 47.3)
		9- 11 months	3178	1675	0.64 (0.56-0.72)	36.4 (28.3 to 43.7)
		12 - 14 months	2603	799	0.62 (0.55-0.71)	37.6 (29.0 to 45.2)
		15+ months	91	34	0.72 (0.48-1.09)	27.8 (-9.4 to 52.4)

Supplementary Table 4. Incremental vaccine effectiveness (iVE) against hospitalisation of at least 4 doses (monovalent vaccines) in individuals aged 75 years and older.

No. of doses	Interval since last dose	Controls	Cases	OR	iVE
3	6+ months	5039	3004	Baseline	Baseline
4+	0 - 13 days	329	125	0.53 (0.43-0.67)	46.7 (33.4 to 57.4)
	2 - 11 weeks	6499	2221	0.48 (0.45-0.52)	51.9 (48.2 to 55.3)
	3 - 5 months	8103	3572	0.73 (0.68-0.78)	26.8 (21.7 to 31.6)
	6 - 9 months	1208	653	1.02 (0.9-1.15)	-1.8 (-15.1 to 10.0)


Supplementary Table 5. Descriptive characteristics of those included the incremental vaccine effectiveness (iVE) analysis of the bivalent BA.1 booster vaccine.

			Overall		Controls		Cases		
			n	%	n	%	n	%	
Vaccination Status	Bivalent vaccine	Interval	49,062	100%	39,108	80%	9,954	20%	
	None		19,108	38.9%	13,945	35.7%	5,163	51.9%	
	Pfizer	0-6 days		408	0.8%	303	0.8%	105	1.1%
		7-13 days		581	1.2%	463	1.2%	118	1.2%
		2-4 weeks		1,917	3.9%	1,649	4.2%	268	2.7%
		5-9 weeks		5,072	10.3%	4,394	11.2%	678	6.8%
		10+ weeks		3,661	7.5%	3,086	7.9%	575	5.8%
	Moderna	0-6 days		279	0.6%	195	0.5%	84	0.8%
		7-13 days		369	0.8%	269	0.7%	100	1.0%
		2-4 weeks		1,462	3.0%	1,156	3.0%	306	3.1%
5-9 weeks			4,404	9.0%	3,760	9.6%	644	6.5%	
10+ weeks			11,801	24.1%	9,888	25.3%	1,913	19.2%	
Gender	Female		25,520	52.0%	20,656	52.8%	4,864	48.9%	
	Male		22,990	46.9%	17,927	45.8%	5,063	50.9%	
	Missing		552	1.1%	525	1.3%	27	0.3%	
Age	50-54		1,968	4.0%	1,655	4.2%	313	3.1%	
	55-59		2,854	5.8%	2,405	6.1%	449	4.5%	
	60-64		3,967	8.1%	3,326	8.5%	641	6.4%	
	65-69		4,954	10.1%	4,042	10.3%	912	9.2%	
	70-74		6,768	13.8%	5,381	13.8%	1,387	13.9%	
	75-79		7,524	15.3%	6,006	15.4%	1,518	15.3%	
	80-84		7,793	15.9%	6,009	15.4%	1,784	17.9%	
	85-89		7,358	15.0%	5,694	14.6%	1,664	16.7%	
	90+		5,876	12.0%	4,590	11.7%	1,286	12.9%	
Ethnicity	African		275	0.6%	213	0.5%	62	0.6%	
	Any other Asian background		410	0.8%	330	0.8%	80	0.8%	
	Any other Black background		130	0.3%	101	0.3%	29	0.3%	
	Any other White background		2,180	4.4%	1,733	4.4%	447	4.5%	
	Any other ethnic group		455	0.9%	370	0.9%	85	0.9%	
	Any other mixed background		154	0.3%	127	0.3%	27	0.3%	
	Bangladeshi or British Bangladeshi		205	0.4%	175	0.4%	30	0.3%	
	British, Mixed British		40,761	83.1%	32,420	82.9%	8,341	83.8%	
	Caribbean		347	0.7%	272	0.7%	75	0.8%	
	Chinese		65	0.1%	53	0.1%	12	0.1%	
	Indian or British Indian		996	2.0%	816	2.1%	180	1.8%	
	Irish		581	1.2%	477	1.2%	104	1.0%	
	Pakistani or British Pakistani		630	1.3%	538	1.4%	92	0.9%	
	White and Asian		42	0.1%	32	0.1%	10	0.1%	
	White and Black African		41	0.1%	32	0.1%	9	0.1%	
	White and Black Caribbean		65	0.1%	49	0.1%	16	0.2%	


	Missing	1,725	3.5%	1,370	3.5%	355	3.6%
NHS Region	East of England	3,830	7.8%	2,985	7.6%	845	8.5%
	London	5,874	12.0%	4,728	12.1%	1,146	11.5%
	Midlands	10,334	21.1%	8,126	20.8%	2,208	22.2%
	North East	10,092	20.6%	8,051	20.6%	2,041	20.5%
	North West	7,488	15.3%	6,263	16.0%	1,225	12.3%
	South East	5,949	12.1%	4,633	11.8%	1,316	13.2%
	South West	5,495	11.2%	4,322	11.1%	1,173	11.8%
	IMD Quintiles	1	11,493	23.4%	9,247	23.6%	2,246
2		9,925	20.2%	7,931	20.3%	1,994	20.0%
3		9,786	19.9%	7,834	20.0%	1,952	19.6%
4		9,325	19.0%	7,382	18.9%	1,943	19.5%
5		8,386	17.1%	6,594	16.9%	1,792	18.0%
Missing		147	0.3%	120	0.3%	27	0.3%
Previously positive	None	37,497	76.4%	28,862	73.8%	8,635	86.7%
	Wild-type	1,203	2.5%	1,042	2.7%	161	1.6%
	Alpha	1,444	2.9%	1,238	3.2%	206	2.1%
	Delta	1,504	3.1%	1,305	3.3%	199	2.0%
	Omicron (before 1st April 2022)	4,276	8.7%	3,778	9.7%	498	5.0%
	Omicron (from 1st April 2022 onwards)	3,138	6.4%	2,883	7.4%	255	2.6%
Risk status	Healthcare worker	316	0.6%	259	0.7%	57	0.6%
	Carehome	2,178	4.4%	1,839	4.7%	339	3.4%
	CaaS autumn booster cohort	44,002	89.7%	34,842	89.1%	9,160	92.0%
	At risk - ever, from NIMS*	7,615	15.5%	6,284	16.1%	1,331	13.4%
	CEV	21,920	44.7%	17,276	44.2%	4,644	46.7%
	Severely immunosuppressed	4,986	10.2%	3,727	9.5%	1,259	12.6%

\*Only for those <65 years

Supplementary Figure 2. Cases (those testing positive) and controls (those testing negative) over time in the bivalent BA.1 booster incremental VE (iVE) analysis.



Supplementary Figure 3. Distribution of time in days since vaccination amongst those who received a bivalent booster.



Supplementary Table 6. Stratified and sensitivity analyses of incremental vaccine effectiveness (iVE) of the bivalent BA.1 booster vaccines against hospitalisation.

Bivalent vaccine	Interval (weeks)	Controls	Cases	Odds Ratio	iVE (95% C.I.)
2+ doses, with a 6 week to 5 month interval to the most recent dose					
None	-	4430	2058	Baseline	Baseline
Pfizer or Moderna	0-6 days	425	142	0.69 (0.56-0.85)	30.5 (14.6 to 43.5)
	7-13 days	431	176	0.76 (0.62-0.92)	24.2 (8.0 to 37.5)
	2-4 weeks	1128	269	0.54 (0.46-0.63)	46.0 (36.8 to 53.8)
	5-9 weeks	1044	163	0.56 (0.46-0.68)	44.2 (31.7 to 54.4)
	10+ weeks	174	26	0.54 (0.34-0.85)	46.3 (14.7 to 66.2)
2+ doses, with a 6 to 8 month interval to the most recent dose					
None	-	2903	1251	Baseline	Baseline
Pfizer or Moderna	0-6 days	195	72	0.6 (0.44-0.8)	40.3 (19.7 to 55.6)
	7-13 days	266	115	0.75 (0.59-0.95)	25.3 (4.6 to 41.5)
	2-4 weeks	1329	348	0.54 (0.46-0.62)	46.5 (37.9 to 53.9)
	5-9 weeks	4489	880	0.61 (0.54-0.68)	39.2 (31.8 to 45.8)
	10+ weeks	7221	1484	0.66 (0.59-0.74)	33.7 (25.7 to 40.8)
2+ doses, with a 9 to 11 month interval to the most recent dose					
None	-	4863	2152	Baseline	Baseline
Pfizer or Moderna	0-6 days	222	90	0.7 (0.54-0.91)	29.7 (8.6 to 45.9)
	7-13 days	302	69	0.44 (0.33-0.58)	55.9 (41.8 to 66.7)
	2-4 weeks	710	124	0.4 (0.33-0.5)	59.9 (50.5 to 67.5)
	5-9 weeks	830	145	0.62 (0.51-0.77)	37.5 (22.9 to 49.3)
	10+ weeks	2067	458	0.76 (0.61-0.94)	24.5 (5.9 to 39.4)
2+ doses, with at least a 12 month interval to the most recent dose					
None	-	6179	1760	Baseline	Baseline
Pfizer or Moderna	0-6 days	81	27	0.8 (0.5-1.28)	20.0 (-28 to 49.9)
	7-13 days	164	34	0.61 (0.42-0.9)	38.7 (9.5 to 58.4)
	2-4 weeks	766	102	0.46 (0.37-0.58)	53.7 (42.1 to 62.9)
	5-9 weeks	2835	297	0.45 (0.39-0.51)	55.4 (48.7 to 61.2)
	10+ weeks	3686	546	0.62 (0.55-0.7)	38.1 (30.2 to 45.0)
2+ doses, with at least a 6 month interval to the most recent dose, all hospital admissions					
None	-	92863	11271	Baseline	Baseline
Pfizer or Moderna	0-6 days	3480	355	0.64 (0.57-0.71)	36.4 (28.7 to 43.2)
	7-13 days	4766	459	0.61 (0.55-0.67)	39.5 (33.1 to 45.2)
	2-4 weeks	18206	1222	0.44 (0.42-0.47)	55.5 (52.5 to 58.3)
	5-9 weeks	39474	2939	0.53 (0.51-0.56)	46.7 (44.1 to 49.2)
	10+ weeks	60294	6158	0.66 (0.63-0.69)	34.3 (31.4 to 37.1)
2+ doses, with at least a 6 month interval to the most recent dose, no adjustment for previous positivity					
None	-	13945	5163	Baseline	Baseline
Pfizer or Moderna	0-6 days	498	189	0.66 (0.55-0.78)	34.4 (21.6 to 45.1)
	7-13 days	732	218	0.58 (0.49-0.68)	42.4 (32.3 to 51.0)
	2-4 weeks	2805	574	0.47 (0.43-0.52)	52.9 (47.9 to 57.5)
	5-9 weeks	8154	1322	0.54 (0.5-0.58)	45.7 (41.5 to 49.7)

	10+ weeks	12974	2488	0.64 (0.6-0.69)	35.9 (31.3 to 40.2)
3+ doses, with at least a 6 month interval to the most recent dose					
None	-	11499	4396	Baseline	Baseline
Pfizer or Moderna	0-6 days	473	184	0.68 (0.57-0.82)	31.8 (18.1 to 43.2)
	7-13 days	711	213	0.59 (0.5-0.7)	40.7 (30.0 to 49.7)
	2-4 weeks	2735	561	0.48 (0.43-0.53)	52.4 (47.1 to 57.1)
	5-9 weeks	8026	1298	0.55 (0.5-0.59)	45.4 (41.0 to 49.5)
	10+ weeks	12827	2473	0.65 (0.6-0.7)	35.2 (30.2 to 39.8)
4+ doses, with at least a 6 month interval to the most recent dose					
None	-	2511	1110	Baseline	Baseline
Pfizer or Moderna	0-6 days	181	74	0.63 (0.47-0.85)	37.3 (15.4 to 53.5)
	7-13 days	264	115	0.75 (0.59-0.96)	24.9 (3.9 to 41.3)
	2-4 weeks	1336	353	0.53 (0.45-0.61)	47.3 (38.9 to 54.6)
	5-9 weeks	4704	913	0.59 (0.53-0.66)	40.9 (33.8 to 47.2)
	10+ weeks	8993	1887	0.67 (0.6-0.74)	33.5 (25.7 to 40.4)
4+ doses, with at a 6 to 8 month interval to the most recent dose					
None	-	2280	1038	Baseline	Baseline
Pfizer or Moderna	0-6 days	175	69	0.6 (0.44-0.81)	40.1 (18.6 to 56.0)
	7-13 days	252	110	0.73 (0.57-0.94)	27.0 (6.1 to 43.3)
	2-4 weeks	1283	339	0.52 (0.45-0.6)	48.1 (39.5 to 55.4)
	5-9 weeks	4381	850	0.59 (0.52-0.66)	41.1 (33.7 to 47.7)
	10+ weeks	7075	1459	0.66 (0.58-0.74)	34.3 (26.1 to 41.6)
Age 75 years+, 4+ doses, with at a 6 to 8 month interval to the most recent dose					
None	-	1931	882	Baseline	Baseline
Pfizer or Moderna	0-6 days	151	61	0.59 (0.42-0.82)	41.0 (17.9 to 57.6)
	7-13 days	229	97	0.69 (0.53-0.9)	31.3 (10.2 to 47.5)
	2-4 weeks	1135	311	0.52 (0.44-0.61)	48.0 (38.8 to 55.7)
	5-9 weeks	3937	784	0.6 (0.53-0.68)	40.0 (32.0 to 47.0)
	10+ weeks	6333	1313	0.66 (0.58-0.75)	33.8 (25.0 to 41.5)
Age 65+, 2+ doses, with at least a 6 month interval to the most recent dose					
None	-	9531	4111	Baseline	Baseline
Pfizer or Moderna	0-6 days	403	164	0.64 (0.53-0.78)	36.0 (22.2 to 47.3)
	7-13 days	575	192	0.58 (0.49-0.69)	42.0 (30.8 to 51.4)
	2-4 weeks	2289	507	0.45 (0.4-0.5)	55.2 (50.0 to 59.9)
	5-9 weeks	6865	1203	0.53 (0.49-0.58)	47.0 (42.5 to 51.1)
	10+ weeks	11741	2311	0.62 (0.58-0.67)	37.7 (32.8 to 42.2)